Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1999 1
2000 6
2001 1
2002 1
2003 2
2004 1
2005 7
2006 7
2007 11
2008 6
2009 6
2010 6
2011 7
2012 22
2013 21
2014 20
2015 25
2016 30
2017 38
2018 21
2019 11
2020 17
2021 26
2022 20
2023 15
2024 14
2025 18

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

301 results

Results by year

Filters applied: . Clear all
Page 1
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trial.
Selmaj KW, Steinman L, Comi G, Bar-Or A, Arnold DL, Hartung HP, Montalbán X, Havrdová EK, Sheffield JK, Krakovich A, Cheng CY, Riolo JV, Pachai C, Thorpe A, DeBoer E, Kappos L, Cohen JA, Cree BA. Selmaj KW, et al. Among authors: havrdova ek. Mult Scler. 2025 Nov;31(13):1557-1571. doi: 10.1177/13524585251382796. Epub 2025 Nov 5. Mult Scler. 2025. PMID: 41190505 Free PMC article.
Moderate-high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosis.
Foong YC, Merlo D, Gresle M, Buzzard K, Horakova D, Havrdova EK, Kalincik T, Roos I, Hodgkinson S, Lechner-Scott J, Lugaresi A, Weinstock-Guttman B, Ozakbas S, Surcinelli A, Foschi M, Boz C, Khoury SJ, Yamout B, Laureys G, Blanco Y, Skibina O, Kuhle J, John N, Alroughani R, Prevost J, Van Pesch V, Tomassini V, Prat A, Girard M, Terzi M, Shaygannejad V, Ampapa R, Gray O, Etemadifar M, Guimarães J, McCombe PA, Gerlach O, Solaro C, Butzkueven H, Zhu C, van der Walt A, Study Group M. Foong YC, et al. Among authors: havrdova ek. J Neurol Neurosurg Psychiatry. 2025 Oct 29:jnnp-2025-336513. doi: 10.1136/jnnp-2025-336513. Online ahead of print. J Neurol Neurosurg Psychiatry. 2025. PMID: 41161724
Serum bilirubin concentrations and their association with clinical and radiological outcomes in multiple sclerosis: A large cohort study.
Uher T, Kleinová P, Woronyczová J, Štěpánek L, Vaněčková M, Krásenský J, Cífková R, Horáková D, Havrdová E, Hoskovec D, Leníček M, Vítek L. Uher T, et al. Among authors: havrdova e. Ann Hepatol. 2025 Sep 22:102117. doi: 10.1016/j.aohep.2025.102117. Online ahead of print. Ann Hepatol. 2025. PMID: 40992627 Free article.
Pregnancy-Related Disease Outcomes in Women With Moderate to Severe Multiple Sclerosis Disability.
Shipley J, Beadnall HN, Sanfilippo PG, Yeh WZ, Horakova D, Havrdova EK, Hradilek P, Kalincik T, Roos I, Prat A, Girard M, Rous Z, Pavelek Z, Gerlach OHH, Lechner-Scott J, Alroughani R, Ozakbas S, Peterka M, Buzzard K, Skibina OG, Maimone D, Foschi M, Surcinelli A, Karabudak R, Spitaleri DLA, Lugaresi A, Tomassini V, Gouider R, Mrabet S, Ferrando BR, Hodgkinson S, Štourac P, Guimarães J, John NA, Macdonell RAL, Meca-Lallana JE, Butzkueven H, van der Walt A, Jokubaitis VG; MSBase Investigator Group. Shipley J, et al. Among authors: havrdova ek. JAMA Netw Open. 2025 Sep 2;8(9):e2531581. doi: 10.1001/jamanetworkopen.2025.31581. JAMA Netw Open. 2025. PMID: 40952740 Free PMC article.
Real-World Laboratory Analysis of Molecular Biomarkers in Multiple Sclerosis Centers in Central-Eastern European Countries Covering 107 Million Inhabitants.
Járdánházy A, Berger T, Hegen H, Hemmer B, Bartosik-Psujek H, Kes VB, Berthele A, Drulovic J, Habek M, Horakova D, Ledinek AH, Havrdova EK, Magyari M, Rejdak K, Tiu C, Turcani P, Bencsik K, Kincses ZT, Vécsei L. Járdánházy A, et al. Among authors: havrdova ek. Int J Mol Sci. 2025 Aug 26;26(17):8274. doi: 10.3390/ijms26178274. Int J Mol Sci. 2025. PMID: 40943201 Free PMC article.
Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis.
Kalincik T, Sharmin S, Roos I, Freedman MS, Atkins H, Massey J, Sutton I, Withers B, Burman J, Torkildsen Ø, Bø L, Lehmann AK, Havrdova EK, Krasulova E, Trneny M, Kozak T, Macdonell R, Brown JWL, Coles A, van der Walt A, Butzkueven H, Van Wijmeersch B, Lechner-Scott J, Barnett M, Laureys G, Willekens B, Buzzard K, Skibina O, Di Gregorio M, Hodgkinson S, Ozakbas S, Meca-Lallana JE, Alroughani R, Prevost J, Foschi M, Surcinelli A, Neri S, Eichau S, McCombe P, John N, Cárdenas-Robledo S, Oh J, Sanchez-Menoyo JL, Patti F, Gerlach O, Blanco Y, Grammond P, Sharrack B, Snowden JA. Kalincik T, et al. Among authors: havrdova ek. Brain. 2025 Aug 4:awaf286. doi: 10.1093/brain/awaf286. Online ahead of print. Brain. 2025. PMID: 40755195 Free article.
Relationship between brain atrophy and disability in a multi-site multiple sclerosis registry.
Nguyen AL, Horakova D, Havrdova EH, Barnett M, Sormani MP, De Stefano N, Battaglini M, Vaneckova M, Lui E, Gaillard F, Desmond PM, Prime H, Datta M, van der Walt A, Jokubaitis VG, Podevyn F, Zivadinov R, Weinstock-Guttman B, D'hooghe MB, Nagels G, Pesch VV, Laureys G, Van Hijfte L, Lechner-Scott J, Patti F, Cristiano E, Rojas JI, Sima DM, Van Hecke W, Kalincik T, Butzkueven H. Nguyen AL, et al. Among authors: havrdova eh. BMJ Neurol Open. 2025 Jul 22;7(2):e001126. doi: 10.1136/bmjno-2025-001126. eCollection 2025. BMJ Neurol Open. 2025. PMID: 40734995 Free PMC article.
Personalized federated learning for predicting disability progression in multiple sclerosis using real-world routine clinical data.
Pirmani A, De Brouwer E, Arany Á, Oldenhof M, Passemiers A, Faes A, Kalincik T, Ozakbas S, Gouider R, Willekens B, Horakova D, Havrdova EK, Patti F, Prat A, Lugaresi A, Tomassini V, Grammond P, Cartechini E, Roos I, Boz C, Alroughani R, Amato MP, Buzzard K, Lechner-Scott J, Guimarães J, Solaro C, Gerlach O, Soysal A, Kuhle J, Sanchez-Menoyo JL, Spitaleri D, Csepany T, Van Wijmeersch B, Ampapa R, Prevost J, Khoury SJ, Van Pesch V, John N, Maimone D, Weinstock-Guttman B, Laureys G, McCombe P, Blanco Y, Altintas A, Al-Asmi A, Garber J, Van der Walt A, Butzkueven H, de Gans K, Rozsa C, Taylor B, Al-Harbi T, Sas A, Rajda C, Gray O, Decoo D, Carroll WM, Kermode AG, Fabis-Pedrini M, Mason D, Perez-Sempere A, Simu M, Shuey N, Singhal B, Cauchi M, Hardy TA, Ramanathan S, Lalive P, Sirbu CA, Hughes S, Castillo Trivino T, Peeters LM, Moreau Y. Pirmani A, et al. Among authors: havrdova ek. NPJ Digit Med. 2025 Jul 24;8(1):478. doi: 10.1038/s41746-025-01788-8. NPJ Digit Med. 2025. PMID: 40707601 Free PMC article.
Ponesimod as add-on treatment in patients with active relapsing multiple sclerosis under dimethyl fumarate (POINT): A phase 3, randomized, placebo-controlled clinical trial.
Kappos L, Burcklen M, D'Ambrosio D, Fox RJ, Freedman MS, Havrdova EK, Hennessy B, Hohlfeld R, Larbalestier A, Lemle A, Lindenstrøm E, Lublin F, Montalban X, Sidorenko T, Sprenger T, Vaclavkova A, Wuerfel J, Pozzilli C. Kappos L, et al. Among authors: havrdova ek. Mult Scler Relat Disord. 2025 Oct;102:106616. doi: 10.1016/j.msard.2025.106616. Epub 2025 Jul 13. Mult Scler Relat Disord. 2025. PMID: 40700861 Clinical Trial.
301 results